Previous 10 | Next 10 |
home / stock / ipcif / ipcif news
TORONTO, ON / ACCESSWIRE / October 14, 2022 / - Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-r...
Intellipharmaceutics International ( OTC:IPCIF ) on Tuesday said it had inked a Canadian license and supply agreement with Taro Pharmaceuticals ( NYSE: TARO ) for depression treatment desvenlafaxine. Shares of OTC-listed IPCIF closed 18.6% higher at $0.10 on Monday whi...
TORONTO, ON / ACCESSWIRE / August 16, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rele...
Intellipharmaceutics International press release ( OTC:IPCIF ): Q2 GAAP EPS of -$0.03. As of May 31, 2022, our cash balance was $372,795. For further details see: Intellipharmaceutics International GAAP EPS of -$0.03
TORONTO, ON / ACCESSWIRE / July 21, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-releas...
TORONTO, ON / ACCESSWIRE / July 15, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and target...
TORONTO, ON / ACCESSWIRE / April 14, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-...
TORONTO, ON / ACCESSWIRE / January 13, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targete...
TORONTO, ON / ACCESSWIRE / December 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted...
TORONTO, ON / ACCESSWIRE / October 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targete...
News, Short Squeeze, Breakout and More Instantly...
Intellipharmaceutics International Inc Company Name:
IPCIF Stock Symbol:
OTCMKTS Market:
Intellipharmaceutics International Inc Website:
TORONTO, ON / ACCESSWIRE / June 14, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI.H) (" Intellipharmaceutics " or the " Company "), announced today that its common stock, currently traded on the OTCQB market, is expected to be downgraded to the OTC Expert Market on J...
MJ Holdings Inc (MJNE) is expected to report for Q1 2024 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.17 for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Luna Innovations Incorporated (LUNA) is expected to report $-0.01 for Q1 2024 Cano Health...
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rel...